---
title: "Small Fiber Neuropathy"
description: "Clinical decision support for small fiber neuropathy diagnosis, etiologic workup, and management"
version: "1.1"
setting: "ED, HOSP, OPD"
status: approved
tags:
  - neuropathy
  - pain
  - autonomic
  - outpatient
---

# Small Fiber Neuropathy

**DIAGNOSIS:** Small Fiber Neuropathy (SFN)
**ICD-10:** G62.9 (Polyneuropathy, unspecified); G62.89 (Other specified polyneuropathies); G90.09 (Other idiopathic peripheral autonomic neuropathy)

**CPT CODES:** 83036 (HbA1c), 82947 (Fasting glucose), 82951 (2-hour oral glucose tolerance test), 80048 (BMP), 85025 (CBC), 82607 (Vitamin B12), 84443 (TSH), 86038 (ANA), 86235 (Anti-SSA (Ro) and anti-SSB (La) antibodies), 83921 (Methylmalonic acid), 86364 (Tissue transglutaminase IgA), 82784 (Total serum IgA), 86701 (HIV), 80061 (Lipid panel), 82306 (Vitamin D), 84425 (Vitamin B1), 84207 (Vitamin B6), 82525 (Copper), 84630 (Zinc), 42400 (Salivary gland biopsy), 82657 (Alpha-galactosidase A enzyme activity), 81405 (GLA gene sequencing), 81404 (TTR gene sequencing), 88313 (Fat pad or skin biopsy, Congo red), 83883 (Serum free light chains), 82164 (Sarcoidosis workup: ACE, chest imaging), 86255 (Paraneoplastic antibody panel), 86157 (Cryoglobulins), 68760 (Schirmer test), 81479 (SCN9A, SCN10A, SCN11A gene testing), 95907-95909 (Nerve conduction studies), 95923 (Quantitative sudomotor axon reflex test, QSART), 95924 (Autonomic reflex screen), 92132 (Corneal confocal microscopy), 95886 (EMG), 72197 (MRI neurography), 78816 (PET-CT), 93306 (Echocardiogram), 75561 (Cardiac MRI)
**SYNONYMS:** SFN; Small fiber sensory neuropathy; Small fiber predominant neuropathy; Pure small fiber neuropathy; Painful small fiber neuropathy; Autonomic small fiber neuropathy; Sensory ganglionopathy (non-length-dependent pattern)
**SCOPE:** Diagnosis and management of small fiber neuropathy presenting with painful sensory and/or autonomic symptoms with normal or near-normal nerve conduction studies. Includes length-dependent and non-length-dependent (ganglionopathy) patterns. Covers etiologic workup for treatable causes, symptomatic pain management, and autonomic symptom treatment.

**VERSION:** 1.1
**CREATED:** January 27, 2026
**REVISED:** January 30, 2026

**STATUS:** Approved

---

**PRIORITY KEY:** STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting

**KEY CLINICAL FEATURES:**
- **Definition:** Neuropathy affecting small myelinated (Aδ) and unmyelinated (C) nerve fibers
- **Sensory symptoms:** Burning pain, allodynia, hyperalgesia, paresthesias, "pins and needles"
- **Autonomic symptoms:** Sudomotor dysfunction (dry skin, hyperhidrosis), orthostatic intolerance, GI dysmotility, urinary symptoms, sicca symptoms
- **Key diagnostic criterion:** Clinical neuropathy with normal or near-normal NCS (which test large fibers only)
- **Gold standard confirmation:** Skin biopsy with reduced intraepidermal nerve fiber density (IENFD)

---

## SECTION A: ACTION ITEMS

---

## 1. LABORATORY WORKUP

### 1A. Essential/Core Labs

| Test (CPT) | ED | HOSP | OPD | ICU | Rationale | Target Finding |
|------------|:--:|:----:|:---:|:---:|-----------|----------------|
| HbA1c (83036) | - | ROUTINE | ROUTINE | - | Diabetes and prediabetes are most common causes of SFN | <5.7% normal; ≥5.7% prediabetes |
| Fasting glucose (82947) | STAT | ROUTINE | ROUTINE | - | Current glycemic status; impaired fasting glucose | <100 mg/dL |
| 2-hour oral glucose tolerance test (82951) | - | ROUTINE | ROUTINE | - | Impaired glucose tolerance causes SFN even with normal HbA1c | 2-hr glucose <140 mg/dL normal |
| BMP (80048) | STAT | ROUTINE | ROUTINE | - | Renal function; medication dosing; uremic neuropathy | eGFR >60; normal electrolytes |
| CBC (85025) | STAT | ROUTINE | ROUTINE | - | Baseline; anemia evaluation | Normal |
| Vitamin B12 (82607) | - | ROUTINE | ROUTINE | - | B12 deficiency causes SFN; common and treatable | >300 pg/mL (>400 optimal) |
| TSH (84443) | - | ROUTINE | ROUTINE | - | Hypothyroidism causes neuropathy | 0.4-4.0 mIU/L |
| ESR, CRP (85652/86140) | - | ROUTINE | ROUTINE | - | Inflammatory markers; vasculitis screen | Normal |
| ANA (86038) | - | ROUTINE | ROUTINE | - | Autoimmune etiology; Sjogren's screen | Negative |
| Anti-SSA (Ro) and anti-SSB (La) antibodies (86235) | - | ROUTINE | ROUTINE | - | Sjogren syndrome is common cause of SFN (up to 40% of SFN) | Negative |
| Hepatitis B and C serologies (87340/86803) | - | ROUTINE | ROUTINE | - | HCV-associated neuropathy; cryoglobulinemia | Negative |

### 1B. Extended Workup (Second-line)

| Test (CPT) | ED | HOSP | OPD | ICU | Rationale | Target Finding |
|------------|:--:|:----:|:---:|:---:|-----------|----------------|
| Methylmalonic acid (83921) | - | ROUTINE | ROUTINE | - | More sensitive for B12 deficiency if B12 borderline (200-400) | Normal (<0.4 μmol/L) |
| Tissue transglutaminase IgA (86364) | - | ROUTINE | ROUTINE | - | Celiac disease causes SFN even without GI symptoms | Negative |
| Total serum IgA (82784) | - | ROUTINE | ROUTINE | - | IgA deficiency causes false-negative TTG | Normal (not deficient) |
| SPEP/UPEP with immunofixation (86335/86334) | - | ROUTINE | ROUTINE | - | Paraproteinemia; monoclonal gammopathy | No monoclonal protein |
| HIV (86701) | - | EXT | ROUTINE | - | HIV-associated sensory neuropathy | Negative |
| Lipid panel (80061) | - | ROUTINE | ROUTINE | - | Metabolic syndrome associated with SFN | Normal/controlled |
| Vitamin D (82306) | - | ROUTINE | ROUTINE | - | Deficiency associated with neuropathic pain | >30 ng/mL |
| Vitamin B1 (84425) | - | ROUTINE | ROUTINE | - | Deficiency causes painful neuropathy | Normal |
| Vitamin B6 (84207) | - | ROUTINE | ROUTINE | - | Both deficiency and excess cause neuropathy | Normal (neither high nor low) |
| Copper (82525) | - | ROUTINE | ROUTINE | - | Copper deficiency neuropathy (especially post-bariatric surgery) | Normal (70-140 μg/dL) |
| Zinc (84630) | - | ROUTINE | ROUTINE | - | Excessive zinc causes copper deficiency | Normal (not elevated) |
| Salivary gland biopsy (42400) | - | - | ROUTINE | - | Sjogren syndrome if clinical suspicion high and serology negative | Negative for lymphocytic infiltration |

### 1C. Rare/Specialized (Refractory or Atypical)

| Test (CPT) | ED | HOSP | OPD | ICU | Rationale | Target Finding |
|------------|:--:|:----:|:---:|:---:|-----------|----------------|
| Alpha-galactosidase A enzyme activity (82657) | - | - | ROUTINE | - | Fabry disease screening (X-linked; consider in males and females) | Normal enzyme activity |
| GLA gene sequencing (81405) | - | - | EXT | - | Confirm Fabry disease if enzyme low or high clinical suspicion | No pathogenic variants |
| TTR gene sequencing (81404) | - | - | ROUTINE | - | Hereditary transthyretin amyloidosis; early SFN with autonomic symptoms | No pathogenic variants |
| Fat pad or skin biopsy, Congo red (88313) | - | - | ROUTINE | - | Amyloidosis if suspected (autonomic features, cardiomyopathy, CTS) | No amyloid deposits |
| Serum free light chains (83883) | - | ROUTINE | ROUTINE | - | AL amyloidosis screen | Normal kappa:lambda ratio |
| Anti-FGFR3 antibodies (86235) | - | - | EXT | - | Autoimmune SFN (especially ganglionopathy pattern) | Negative |
| Anti-TS-HDS antibodies (86235) | - | - | EXT | - | Autoimmune SFN marker | Negative |
| Sarcoidosis workup: ACE, chest imaging (82164) | - | ROUTINE | ROUTINE | - | Sarcoid neuropathy | Normal ACE; no hilar adenopathy |
| Paraneoplastic antibody panel (86255) | - | ROUTINE | ROUTINE | - | Paraneoplastic sensory ganglionopathy (anti-Hu) if rapid onset | Negative |
| Cryoglobulins (86157) | - | - | EXT | - | Cryoglobulinemic neuropathy (especially with HCV) | Negative |
| Schirmer test (68760) | - | - | ROUTINE | - | Objective dry eye for Sjogren diagnosis | Normal (>5mm in 5 min) |
| SCN9A, SCN10A, SCN11A gene testing (81479) | - | - | EXT | - | Sodium channelopathies causing inherited SFN (erythromelalgia) | No pathogenic variants |

---

## 2. DIAGNOSTIC IMAGING & STUDIES

### 2A. Essential/First-line

| Study (CPT) | ED | HOSP | OPD | ICU | Timing | Target Finding | Contraindications |
|-------------|:--:|:----:|:---:|:---:|--------|----------------|-------------------|
| Nerve conduction studies (95907-95909) | - | ROUTINE | ROUTINE | - | At initial evaluation | Normal or near-normal (SFN spares large fibers) | None |
| Skin biopsy, 3mm punch at distal leg and thigh (88305/88342) | - | - | ROUTINE | - | After NCS shows normal large fiber function | Reduced IENFD below normative threshold for age/sex/site | Bleeding diathesis; anticoagulation (relative) |

### 2B. Extended

| Study (CPT) | ED | HOSP | OPD | ICU | Timing | Target Finding | Contraindications |
|-------------|:--:|:----:|:---:|:---:|--------|----------------|-------------------|
| Quantitative sudomotor axon reflex test, QSART (95923) | - | - | ROUTINE | - | Autonomic symptoms; suspected sudomotor dysfunction | Normal sweat volumes at all sites | None |
| Sudoscan (95923) | - | - | ROUTINE | - | Screening for sudomotor dysfunction; non-invasive | Normal electrochemical skin conductance hands and feet | None |
| Autonomic reflex screen (95924) | - | EXT | ROUTINE | - | Comprehensive autonomic evaluation; orthostatic symptoms | Normal cardiovagal, adrenergic, and sudomotor function | None |
| Tilt table test (95924) | - | EXT | ROUTINE | - | Orthostatic intolerance; POTS evaluation | No excessive HR rise; no orthostatic hypotension | None |
| Quantitative sensory testing, QST (95924) | - | - | EXT | - | Thermal threshold testing; research and specialized centers | Normal thermal detection thresholds | None |
| Thermoregulatory sweat test (95924) | - | - | EXT | - | Global sudomotor evaluation if QSART equivocal | Normal sweat distribution | Cardiac instability |
| Corneal confocal microscopy (92132) | - | - | EXT | - | Non-invasive small fiber assessment; research tool | Normal corneal nerve fiber density and length | None |

### 2C. Rare/Specialized

| Study (CPT) | ED | HOSP | OPD | ICU | Timing | Target Finding | Contraindications |
|-------------|:--:|:----:|:---:|:---:|--------|----------------|-------------------|
| EMG (95886) | - | ROUTINE | ROUTINE | - | If large fiber involvement suspected; atypical features | Normal (SFN spares motor and large sensory fibers) | Anticoagulation (relative) |
| MRI spine, cervical/thoracic (72141/72146) | - | ROUTINE | ROUTINE | - | Ganglionopathy pattern; non-length-dependent SFN | Normal dorsal root ganglia; no dorsal column signal | MRI contraindications |
| MRI neurography (72197) | - | - | EXT | - | Research; visualize small nerves | No nerve enlargement or signal abnormality | MRI contraindications |
| PET-CT (78816) | - | EXT | EXT | - | Sarcoidosis or malignancy suspected; paraneoplastic evaluation | No abnormal uptake | Pregnancy |
| Echocardiogram (93306) | - | ROUTINE | ROUTINE | - | Amyloidosis suspected (cardiomyopathy screening) | No infiltrative cardiomyopathy features | None |
| Cardiac MRI (75561) | - | EXT | EXT | - | Cardiac amyloidosis evaluation if echo abnormal | No amyloid infiltration | MRI contraindications; devices |

---

## 3. TREATMENT

### 3A. Acute/Emergent

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| IV fluids | IV | Acute orthostatic hypotension with symptoms | 500-1000 mL :: IV :: bolus :: 500-1000 mL NS bolus for symptomatic orthostatic hypotension; avoid in heart failure | Heart failure; volume overload | Volume status; BP response | STAT | STAT | - | STAT |
| Pain crisis management | IV/PO | Severe acute neuropathic pain flare not responding to outpatient regimen | Multimodal :: IV/PO :: PRN :: IV lidocaine infusion (1-3 mg/kg/hr) if refractory; avoid chronic opioids | Lidocaine: cardiac conduction abnormality | Pain scores; cardiac monitoring for lidocaine | URGENT | URGENT | - | URGENT |
| Glucose management | Various | Acute presentation with new diabetes diagnosis | Per protocol :: Various :: per protocol :: Initiate diabetes management; hypoglycemia causes SFN flare | Per specific agent | Glucose | STAT | STAT | - | STAT |

### 3B. Symptomatic Treatments (Neuropathic Pain - First-line)

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Duloxetine | PO | First-line for neuropathic pain; also treats depression/anxiety common in SFN | 30 mg :: PO :: daily :: Start 30 mg daily x 1 week; increase to 60 mg daily; max 120 mg/day | MAOIs; uncontrolled narrow-angle glaucoma; severe renal impairment (CrCl <30) | Hepatic function; BP; suicidal ideation | - | ROUTINE | ROUTINE | - |
| Pregabalin | PO | First-line for neuropathic pain; FDA-approved for postherpetic neuralgia and DPN | 50 mg :: PO :: TID :: Start 50 mg TID or 75 mg BID; titrate q3-7d; max 300 mg/day; reduce if CrCl <60 | Angioedema to pregabalin/gabapentin | Dizziness, somnolence, weight gain, peripheral edema | - | ROUTINE | ROUTINE | - |
| Gabapentin | PO | First-line; less expensive alternative to pregabalin | 300 mg :: PO :: qHS :: Start 300 mg qHS; titrate by 300 mg q3-7d; target 1800-3600 mg/day divided TID; reduce if CrCl <60 | Severe renal impairment (dose adjust required) | Sedation, dizziness, ataxia, edema | - | ROUTINE | ROUTINE | - |
| Amitriptyline | PO | TCA for neuropathic pain; helps insomnia; inexpensive | 10 mg :: PO :: qHS :: Start 10-25 mg qHS; titrate by 10-25 mg q1-2wk; typical 25-75 mg qHS; max 150 mg | Cardiac conduction disease; recent MI; urinary retention; narrow-angle glaucoma; elderly (high anticholinergic burden) | ECG if age >40 or cardiac history; anticholinergic side effects | - | ROUTINE | ROUTINE | - |
| Nortriptyline | PO | TCA with less sedation and anticholinergic effects than amitriptyline | 10 mg :: PO :: qHS :: Start 10-25 mg qHS; titrate by 10-25 mg q1-2wk; typical 25-75 mg qHS | Cardiac conduction disease; recent MI; urinary retention; narrow-angle glaucoma | ECG if dose >100 mg/day or cardiac risk factors | - | ROUTINE | ROUTINE | - |
| Venlafaxine XR | PO | SNRI alternative to duloxetine | 37.5 mg :: PO :: daily :: Start 37.5 mg daily; increase by 37.5-75 mg q1wk; target 150-225 mg daily | MAOIs; uncontrolled hypertension | BP at higher doses; discontinuation syndrome if stopped abruptly | - | ROUTINE | ROUTINE | - |

### 3C. Second-line/Refractory (Neuropathic Pain)

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Capsaicin 8% patch (Qutenza) | Topical | Localized neuropathic pain; add-on therapy | 1 patch :: Topical :: q3mo :: Applied by trained healthcare provider; pre-treat with topical anesthetic; may repeat q3mo | Application to face/mucous membranes; broken skin | Pain/burning during application; transient BP increase | - | - | ROUTINE | - |
| Lidocaine 5% patch | Topical | Localized pain; adjunctive therapy; allodynia | 1-3 patches :: Topical :: daily :: Apply to most painful area; up to 3 patches for 12h on/12h off | Allergy to local anesthetics; damaged skin | Skin irritation | - | ROUTINE | ROUTINE | - |
| Lamotrigine | PO | Sodium channel blocker; some evidence in SFN | 25 mg :: PO :: daily :: Start 25 mg daily x 2wk; then 50 mg daily x 2wk; increase by 50 mg q2wk; max 400 mg/day | SJS/TEN history; valproate use (reduce dose by 50%) | RASH (especially first 8 weeks) - stop immediately if rash | - | ROUTINE | ROUTINE | - |
| Lacosamide | PO | Sodium channel blocker; well-tolerated | 50 mg :: PO :: BID :: Start 50 mg BID; increase by 50 mg/day weekly; max 400 mg/day | Second or third degree AV block (without pacemaker) | ECG for PR prolongation; dizziness | - | ROUTINE | ROUTINE | - |
| Carbamazepine | PO | Sodium channel blocker; limited evidence for SFN specifically | 100 mg :: PO :: BID :: Start 100 mg BID; titrate by 200 mg/wk; max 1200 mg/day | AV block; bone marrow suppression; HLA-B*1502 in Asian patients (SJS risk) | CBC, LFTs, sodium; drug interactions (CYP3A4 inducer) | - | ROUTINE | ROUTINE | - |
| Mexiletine | PO | Sodium channel blocker; especially if SCN9A mutation suspected | 150 mg :: PO :: TID :: Start 150 mg TID; titrate by 150 mg q3d; max 1200 mg/day; take with food | Cardiomyopathy; second/third degree AV block | ECG; arrhythmia monitoring | - | EXT | ROUTINE | - |
| Desipramine | PO | TCA with minimal anticholinergic effects | 25 mg :: PO :: qHS :: Start 25 mg qHS; titrate by 25 mg q1-2wk; target 50-100 mg | Same as other TCAs | ECG; drug levels available if needed | - | ROUTINE | ROUTINE | - |
| Tramadol | PO | Moderate pain; opioid-like with serotonergic properties | 50 mg :: PO :: q6h PRN :: Start 50 mg q6h PRN; max 400 mg/day; reduce if renal/hepatic impairment | Seizure disorder; concurrent MAOIs/SSRIs (serotonin syndrome risk) | Seizures, serotonin syndrome, constipation | - | ROUTINE | ROUTINE | - |
| Tapentadol ER | PO | Refractory pain; mu-opioid agonist with norepinephrine reuptake inhibition | 50 mg :: PO :: BID :: Start 50 mg BID; titrate by 50 mg BID q3d; max 500 mg/day | Severe respiratory depression; MAOIs; paralytic ileus | Respiratory status, constipation, sedation | - | EXT | ROUTINE | - |
| Combination therapy | Various | Inadequate response to monotherapy | Per regimen :: Various :: per regimen :: Gabapentinoid + SNRI; TCA + gabapentinoid; use lower doses of each | Per individual agents | Additive side effects; falls in elderly | - | ROUTINE | ROUTINE | - |
| Low-dose naltrexone (LDN) | PO | Emerging evidence for neuropathic pain; anti-inflammatory | 1.5 mg :: PO :: qHS :: Start 1.5 mg qHS; increase by 1.5 mg q2wk; max 4.5 mg; compounded | Current opioid use; hepatic impairment | Vivid dreams, insomnia (take in AM if occurs) | - | - | EXT | - |
| Spinal cord stimulation | Implant | Refractory SFN pain; failed multiple medications | Per protocol :: Implant :: per protocol :: Trial stimulation before permanent implant; high-frequency or burst stimulation preferred | Infection; coagulopathy; psychiatric instability | Device function; pain relief | - | - | EXT | - |

### 3D. Autonomic Symptom Management

| Treatment | Route | Indication | Dosing | Pre-Treatment Requirements | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|---------------------------|-------------------|------------|:--:|:----:|:---:|:---:|
| Fludrocortisone | PO | Orthostatic hypotension; volume expansion | 0.1 mg :: PO :: daily :: Start 0.1 mg daily; may increase to 0.2 mg daily; max 0.3 mg | Check potassium; assess volume status | Heart failure; hypertension; hypokalemia | Weight, BP supine and standing, potassium, edema | - | ROUTINE | ROUTINE | - |
| Midodrine | PO | Orthostatic hypotension; alpha-1 agonist vasoconstrictor | 2.5 mg :: PO :: TID :: Start 2.5 mg TID (with meals); titrate to 5-10 mg TID; last dose 4h before bed | None specific | Severe cardiac disease; urinary retention; supine hypertension | Supine BP (check for supine hypertension); avoid at bedtime | - | ROUTINE | ROUTINE | - |
| Droxidopa (Northera) | PO | Neurogenic orthostatic hypotension; FDA-approved for autonomic failure | 100 mg :: PO :: TID :: Start 100 mg TID; titrate by 100 mg/day q24-48h; max 600 mg TID | None specific | Supine hypertension (severe) | Supine BP; avoid lying flat for 2h after dose | - | ROUTINE | ROUTINE | - |
| Pyridostigmine | PO | Orthostatic hypotension; enhances ganglionic transmission | 30 mg :: PO :: TID :: Start 30 mg TID; may increase to 60 mg TID; modest BP effect but no supine hypertension | None specific | Mechanical GI/GU obstruction; bradyarrhythmia | Cholinergic effects (diarrhea, salivation) | - | ROUTINE | ROUTINE | - |
| Compression stockings | External | Orthostatic hypotension; venous pooling | 30-40 mmHg :: External :: daily :: Waist-high preferred over knee-high; put on before rising; 30-40 mmHg compression | Peripheral arterial disease (ABI <0.5) | None absolute if ABI >0.5 | Skin integrity; ABI if arterial disease suspected | - | ROUTINE | ROUTINE | - |
| Oxybutynin | PO | Bladder urgency/frequency | 5 mg :: PO :: BID :: Start 5 mg BID or 10 mg XL daily; max 30 mg/day | None specific | Urinary retention; uncontrolled narrow-angle glaucoma; GI obstruction | Anticholinergic effects; cognition in elderly | - | ROUTINE | ROUTINE | - |
| Solifenacin | PO | Bladder urgency; better tolerated anticholinergic | 5 mg :: PO :: daily :: Start 5 mg daily; may increase to 10 mg daily | None specific | Same as oxybutynin; severe hepatic impairment | Anticholinergic effects | - | ROUTINE | ROUTINE | - |
| Mirabegron | PO | Bladder urgency; beta-3 agonist (non-anticholinergic) | 25 mg :: PO :: daily :: Start 25 mg daily; may increase to 50 mg daily | None specific | Uncontrolled hypertension; severe hepatic impairment | BP; urinary retention | - | ROUTINE | ROUTINE | - |
| Metoclopramide | PO | Gastroparesis; prokinetic | 5 mg :: PO :: AC :: 5-10 mg 30 min before meals and at bedtime; limit to <12 weeks | None specific | Tardive dyskinesia (limit duration); GI obstruction; Parkinson disease | Tardive dyskinesia; extrapyramidal symptoms | - | ROUTINE | ROUTINE | - |
| Domperidone | PO | Gastroparesis; prokinetic with less CNS effects | 10 mg :: PO :: TID :: 10 mg TID before meals; not FDA-approved (requires IND or international pharmacy) | ECG baseline for QT | QT prolongation; ventricular arrhythmia | ECG for QT; arrhythmia | - | - | EXT | - |
| Erythromycin | PO | Gastroparesis; motilin receptor agonist | 250 mg :: PO :: TID :: 250 mg PO TID before meals; short-term use due to tachyphylaxis | ECG baseline for QT | QT prolongation; drug interactions | ECG; GI upset; tachyphylaxis limits long-term use | - | ROUTINE | ROUTINE | - |
| Sildenafil | PO | Erectile dysfunction in autonomic SFN | 25 mg :: PO :: PRN :: Start 25-50 mg 1h before activity; max 100 mg; avoid with nitrates | Cardiovascular assessment | Nitrate use; severe cardiovascular disease | Cardiovascular status; vision changes | - | - | ROUTINE | - |

### 3E. Disease-Modifying / Etiology-Targeted Therapies

| Treatment | Route | Indication | Dosing | Pre-Treatment Requirements | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|---------------------------|-------------------|------------|:--:|:----:|:---:|:---:|
| Glycemic control optimization | Various | Diabetes/prediabetes-associated SFN | Per guidelines :: Various :: per protocol :: Lifestyle first for prediabetes; HbA1c <7% target; tighter control slows progression | Diabetes education | Hypoglycemia risk | HbA1c q3-6mo; glucose monitoring | - | ROUTINE | ROUTINE | - |
| IVIG | IV | Autoimmune SFN (Sjogren-associated; anti-FGFR3+; idiopathic with evidence of inflammation) | 2 g/kg :: IV :: divided over 2-5 days monthly :: 2 g/kg divided over 2-5 days monthly; limited evidence; consider trial | Check IgA level (IgA-deficient patients need IgA-depleted product) | IgA deficiency (use IgA-depleted); renal impairment; hypercoagulable state | Renal function; thrombotic risk; headache | - | ROUTINE | ROUTINE | - |
| Enzyme replacement therapy — Fabry disease | IV | Fabry disease-associated SFN | 1 mg/kg :: IV :: q2wk :: Agalsidase beta (Fabrazyme) 1 mg/kg IV q2wk; lifelong therapy; infusion reactions common early | Genetic confirmation of Fabry disease | None absolute | Infusion reactions; anti-drug antibodies | - | ROUTINE | ROUTINE | - |
| Tafamidis (Vyndamax/Vyndaqel) | PO | Hereditary and wild-type TTR amyloidosis with polyneuropathy | 80 mg :: PO :: daily :: 80 mg (Vyndamax) or 61 mg (Vyndaqel) PO daily; TTR stabilizer | Genetic confirmation of TTR amyloidosis | None | Cardiac function; neuropathy progression | - | - | ROUTINE | - |
| Inotersen/Patisiran | SC/IV | Hereditary TTR amyloidosis with polyneuropathy | Per protocol :: SC/IV :: per protocol :: Inotersen 284 mg SC weekly; Patisiran 0.3 mg/kg IV q3wk | TTR gene mutation confirmed; specialist management | Thrombocytopenia (inotersen); infusion reactions | Platelets (inotersen); hepatic function | - | - | EXT | - |
| Gluten-free diet | Diet | Celiac disease-associated SFN | Strict gluten-free :: Diet :: daily :: Lifelong strict gluten-free diet; dietitian referral; neuropathy may stabilize/improve | Celiac confirmation (biopsy or serology) | None | TTG-IgA levels; symptom response | - | - | ROUTINE | - |
| B12 supplementation | PO/IM | B12 deficiency-associated SFN | 1000 mcg :: PO :: daily :: 1000-2000 mcg PO daily; or 1000 mcg IM weekly x 4, then monthly if poor absorption | Confirmed B12 deficiency | None | B12 and MMA levels q3-6mo until stable | - | ROUTINE | ROUTINE | - |
| Immunosuppression (Sjogren's) | Various | Sjogren's-associated SFN with systemic disease activity | Per rheumatology :: Various :: per protocol :: Hydroxychloroquine, methotrexate, rituximab; coordinate with rheumatology | Rheumatology co-management | Per specific agent | Per specific agent | - | ROUTINE | ROUTINE | - |
| Alpha-lipoic acid | PO | Antioxidant; some evidence in painful neuropathy; European guidelines | 600 mg :: PO :: daily :: 600 mg PO daily; may take 3-6 months for effect; limited evidence | None | GI upset | May enhance hypoglycemia in diabetics | - | - | ROUTINE | - |

---

## 4. OTHER RECOMMENDATIONS

### 4A. Referrals & Consults

| Recommendation | ED | HOSP | OPD | ICU |
|----------------|:--:|:----:|:---:|:---:|
| Neuromuscular specialist for skin biopsy interpretation and complex SFN management | - | ROUTINE | ROUTINE | - |
| Rheumatology if Sjogren's, lupus, or other connective tissue disease suspected | - | ROUTINE | ROUTINE | - |
| Endocrinology if diabetes/prediabetes for glycemic optimization and metabolic management | - | ROUTINE | ROUTINE | - |
| Genetics counselor if hereditary etiology suspected (Fabry, TTR amyloidosis, SCN9A channelopathies) | - | - | ROUTINE | - |
| Gastroenterology for celiac confirmation, gastroparesis management, or liver biopsy if amyloid suspected | - | ROUTINE | ROUTINE | - |
| Cardiology if TTR amyloidosis suspected or autonomic symptoms with cardiac involvement | - | ROUTINE | ROUTINE | - |
| Pain management for refractory neuropathic pain and interventional options (spinal cord stimulation) | - | - | ROUTINE | - |
| Physical therapy for balance training, strengthening, and fall prevention | - | ROUTINE | ROUTINE | - |
| Autonomic disorders specialist if complex autonomic symptoms (POTS, orthostatic hypotension) | - | - | ROUTINE | - |
| Psychiatry/psychology for chronic pain coping and comorbid depression/anxiety management | - | - | ROUTINE | - |
| Hematology/oncology if amyloidosis confirmed for staging and treatment | - | ROUTINE | ROUTINE | - |

### 4B. Patient Instructions

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| Report any new weakness, gait difficulty, or falls as these may indicate progression to large fiber involvement | STAT | STAT | ROUTINE |
| Monitor for signs of infection in feet (redness, warmth, drainage) if sensation is impaired | - | ROUTINE | ROUTINE |
| Keep a pain diary to track triggers, severity, and medication response | - | ROUTINE | ROUTINE |
| Rise slowly from sitting or lying to prevent falls from orthostatic hypotension | STAT | ROUTINE | ROUTINE |
| Increase salt and fluid intake (2-3L/day, 6-10g sodium) if orthostatic hypotension present (unless contraindicated) | - | ROUTINE | ROUTINE |
| Wear compression stockings before rising in the morning if orthostatic hypotension diagnosed | - | ROUTINE | ROUTINE |
| Take all prescribed pain medications as directed; do not stop gabapentinoids or SNRIs abruptly | - | ROUTINE | ROUTINE |
| Avoid excessive heat exposure which can worsen symptoms; stay hydrated in warm weather | - | ROUTINE | ROUTINE |
| Return if severe headache, vision changes, or syncope develop (may indicate medication side effects or disease progression) | STAT | STAT | ROUTINE |

### 4C. Lifestyle & Prevention

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| Strict glycemic control (HbA1c <7% or <5.7% if prediabetes) to prevent progression; lifestyle modifications first | - | ROUTINE | ROUTINE |
| Alcohol cessation as alcohol independently causes and worsens small fiber neuropathy | - | ROUTINE | ROUTINE |
| Smoking cessation as smoking impairs nerve regeneration and worsens outcomes | - | ROUTINE | ROUTINE |
| Regular low-impact exercise (swimming, stationary bike, walking) to improve pain and maintain function | - | ROUTINE | ROUTINE |
| Healthy diet (Mediterranean or DASH) to optimize metabolic health and reduce inflammation | - | ROUTINE | ROUTINE |
| Weight management as metabolic syndrome is associated with SFN | - | ROUTINE | ROUTINE |
| Sleep hygiene to improve sleep quality; chronic pain worsens with poor sleep | - | ROUTINE | ROUTINE |
| Stress reduction techniques (mindfulness, meditation) as stress can amplify pain perception | - | ROUTINE | ROUTINE |
| Fall prevention with home safety evaluation given proprioceptive deficits and orthostatic hypotension | - | ROUTINE | ROUTINE |
| Avoid B6 (pyridoxine) supplementation above RDA (1.3-2 mg/day) as excess causes neuropathy | - | ROUTINE | ROUTINE |

---

## SECTION B: REFERENCE

---

## 5. DIFFERENTIAL DIAGNOSIS

| Alternative Diagnosis | Key Distinguishing Features | Tests to Differentiate |
|-----------------------|----------------------------|------------------------|
| Diabetic polyneuropathy (large fiber) | NCS abnormal; mixed sensorimotor findings; more numbness than pain | EMG/NCS shows axonal polyneuropathy |
| Fibromyalgia | Widespread pain; tender points; normal skin biopsy; chronic fatigue | ACR criteria; normal IENFD on skin biopsy |
| Complex regional pain syndrome (CRPS) | Regional rather than length-dependent; swelling, color changes, dystrophy | Budapest criteria; regional distribution |
| Erythromelalgia | Intermittent burning with redness and warmth; triggered by heat; may have SCN9A mutation | Clinical pattern; genetic testing if suspected |
| Central sensitization syndromes | Normal peripheral testing; pain out of proportion to objective findings | QST pattern; skin biopsy normal |
| Psychogenic/functional sensory symptoms | Non-anatomical distribution; inconsistent findings; psychiatric comorbidity | Careful neurological exam; normal objective testing |
| Vitamin B12 deficiency | May have subacute combined degeneration; cognitive changes; macrocytic anemia | B12, MMA levels; MRI spine |
| Lyme disease | Endemic area; prior tick bite; rash history; may have radiculopathy | Lyme serology (ELISA + Western blot) |
| Hereditary sensory neuropathy (HSAN) | Family history; anhidrosis; painless injuries; mutilating features | Genetic testing (HSAN genes) |
| Burning mouth syndrome | Isolated to oral mucosa; taste changes; dry mouth | Location-specific; oral exam |
| Restless legs syndrome | Urge to move legs; worse at rest/night; relief with movement | Clinical criteria; may coexist with SFN |
| Vasculitic neuropathy | Asymmetric; mononeuritis multiplex pattern; systemic symptoms; rapid onset | Nerve biopsy; inflammatory markers; angiography |
| Paraneoplastic sensory ganglionopathy | Subacute onset; asymmetric; non-length-dependent; cancer history/risk | Anti-Hu antibodies; CT chest/abdomen/pelvis |

---

## 6. MONITORING PARAMETERS

| Parameter | Frequency | Target/Threshold | Action if Abnormal | ED | HOSP | OPD | ICU |
|-----------|-----------|------------------|-------------------|:--:|:----:|:---:|:---:|
| Pain scores (NRS, VAS, BPI) | Each visit | 50%+ reduction or functional improvement | Adjust medications; consider combination or referral | - | ROUTINE | ROUTINE | - |
| HbA1c (if diabetes/prediabetes) | Every 3-6 months | <7% (or <5.7% if prediabetes) | Intensify glycemic management | - | ROUTINE | ROUTINE | - |
| Orthostatic vitals (lying, sitting, standing) | Each visit if autonomic symptoms | SBP drop <20 mmHg; no symptoms | Adjust autonomic medications; hydration; compression | STAT | ROUTINE | ROUTINE | - |
| Repeat skin biopsy (IENFD) | Every 1-2 years if monitoring disease course | Stable or improved IENFD | Intensify etiology treatment if declining | - | - | ROUTINE | - |
| Autonomic symptoms inventory | Each visit | Stable or improved | Adjust autonomic treatments; workup new symptoms | - | ROUTINE | ROUTINE | - |
| ECG | Baseline if on TCAs or sodium channel blockers; periodically | Normal PR, QRS, QTc intervals | Dose reduction or discontinuation if prolonged intervals | - | ROUTINE | ROUTINE | - |
| Renal function (eGFR) | Every 6-12 months | eGFR >60 or stable | Adjust medication doses; nephrology referral | - | ROUTINE | ROUTINE | - |
| Potassium (if on fludrocortisone) | Monthly initially, then every 3-6 months | 3.5-5.0 mEq/L | Supplement potassium; reduce fludrocortisone dose | - | ROUTINE | ROUTINE | - |
| Weight and edema | Each visit | Stable weight; no edema | Adjust pregabalin/gabapentin or autonomic meds | - | ROUTINE | ROUTINE | - |
| Depression screen (PHQ-9) | Every 6-12 months | <5 (no depression) | Mental health referral; consider duloxetine/venlafaxine | - | ROUTINE | ROUTINE | - |
| Falls assessment | Each visit | No falls | PT referral; home safety; reduce sedating medications | - | ROUTINE | ROUTINE | - |

---

## 7. DISPOSITION CRITERIA

| Disposition | Criteria |
|-------------|----------|
| Discharge home | Symptoms stable; pain controlled; autonomic symptoms not causing hemodynamic instability; follow-up arranged |
| Admit to floor | Severe uncontrolled pain requiring IV medications; syncope from orthostatic hypotension; new diagnosis requiring urgent workup (suspected amyloidosis with cardiac involvement) |
| Admit to ICU | Hemodynamically unstable from autonomic dysfunction; severe symptomatic bradycardia or hypotension |
| Outpatient follow-up | Every 3-6 months for medication optimization; annually for etiology reassessment if initially idiopathic |

---

## 8. EVIDENCE & REFERENCES

| Recommendation | Evidence Level | Source |
|----------------|----------------|--------|
| Skin biopsy (IENFD) as diagnostic standard for SFN | Class II, Level B | [Lauria et al. European Journal of Neurology 2010](https://pubmed.ncbi.nlm.nih.gov/20298428/) |
| QSART for sudomotor function assessment in SFN | Class II, Level B | [Low et al. Muscle & Nerve 1983](https://pubmed.ncbi.nlm.nih.gov/6652106/) |
| Impaired glucose tolerance as cause of SFN | Class II, Level B | [Singleton et al. Neurology 2001](https://pubmed.ncbi.nlm.nih.gov/11706115/) |
| Sjogren syndrome associated with SFN | Class II, Level B | [Chai et al. Annals of Neurology 2005](https://pubmed.ncbi.nlm.nih.gov/17282462/) |
| Duloxetine for neuropathic pain | Class I, Level A | [Lunn et al. Cochrane 2014](https://pubmed.ncbi.nlm.nih.gov/24385423/) |
| Gabapentin for neuropathic pain | Class I, Level A | [Wiffen et al. Cochrane 2017](https://pubmed.ncbi.nlm.nih.gov/28597471/) |
| Pregabalin for neuropathic pain | Class I, Level A | [Derry et al. Cochrane 2019](https://pubmed.ncbi.nlm.nih.gov/30673120/) |
| TCAs for neuropathic pain | Class II, Level B | [Moore et al. Cochrane 2015](https://pubmed.ncbi.nlm.nih.gov/25879104/) |
| Fludrocortisone for orthostatic hypotension | Class II, Level C | [Freeman et al. Neurology 2018 Consensus Statement](https://pubmed.ncbi.nlm.nih.gov/29666232/) |
| Midodrine for orthostatic hypotension | Class I, Level A | [Wright et al. Am Heart J 1998](https://pubmed.ncbi.nlm.nih.gov/18301662/) |
| Droxidopa for neurogenic orthostatic hypotension | Class I, Level A | [Biaggioni et al. Neurology 2015](https://pubmed.ncbi.nlm.nih.gov/25757803/) |
| IVIG for autoimmune SFN | Class III, Level C | [Liu et al. J Periph Nerv Syst 2014](https://pubmed.ncbi.nlm.nih.gov/24750390/) |
| Fabry disease as cause of SFN | Class II, Level B | [Biegstraaten et al. Orphanet J Rare Dis 2012](https://pubmed.ncbi.nlm.nih.gov/22497776/) |
| TTR amyloidosis neuropathy treatment | Class I, Level A | [Adams et al. NEJM 2018 (Patisiran trial)](https://pubmed.ncbi.nlm.nih.gov/29972757/) |
| Sodium channelopathies (SCN9A) in SFN | Class II, Level B | [Faber et al. Ann Neurol 2012](https://pubmed.ncbi.nlm.nih.gov/21698661/) |

---

## CHANGE LOG

**v1.1 (January 30, 2026)**
- Standardized lab tables: reordered columns to `Test (CPT) | ED | HOSP | OPD | ICU | Rationale | Target Finding`
- Added CPT codes to all lab tests (1A: 11 rows, 1B: 12 rows, 1C: 12 rows)
- Standardized imaging tables: reordered columns to `Study (CPT) | ED | HOSP | OPD | ICU | Timing | Target Finding | Contraindications`
- Added CPT codes to all imaging studies (2A: 2 rows, 2B: 7 rows, 2C: 6 rows)
- Fixed structured dosing first fields across all treatment sections (3A-3E): starting dose only in first field
- Renamed CLINICAL SYNONYMS to SYNONYMS
- Added VERSION/CREATED/REVISED header block
- Moved SYNONYMS before SCOPE in header

**v1.0 (January 27, 2026)**
- Initial template creation
- Comprehensive etiologic workup (diabetes, Sjogren's, amyloidosis, Fabry, celiac)
- Diagnostic approach with skin biopsy and autonomic testing
- Neuropathic pain treatment with structured dosing format
- Autonomic symptom management section
- Disease-modifying therapies for treatable causes
- Differentiation of length-dependent vs non-length-dependent patterns

---

## APPENDIX A: SFN Diagnostic Criteria

### Clinical Features Suggesting SFN

| Symptom Category | Examples |
|------------------|----------|
| **Positive sensory symptoms** | Burning pain; electric shock sensations; tingling; allodynia; hyperalgesia |
| **Negative sensory symptoms** | Numbness; thermal hypoesthesia (can't feel hot/cold) |
| **Autonomic symptoms** | Dry eyes/mouth; sweating abnormalities; orthostatic intolerance; GI dysmotility; urinary dysfunction; erectile dysfunction |
| **Distribution** | Length-dependent (feet > hands) OR non-length-dependent (patchy, proximal, asymmetric) |

### Diagnostic Certainty Levels

| Level | Criteria |
|-------|----------|
| **Possible SFN** | Clinical symptoms and signs compatible with SFN |
| **Probable SFN** | Clinical features + abnormal QST thermal thresholds OR abnormal QSART |
| **Definite SFN** | Clinical features + reduced IENFD on skin biopsy below age/sex/site normative values |

### Length-Dependent vs Non-Length-Dependent (Ganglionopathy) Pattern

| Feature | Length-Dependent | Non-Length-Dependent |
|---------|------------------|----------------------|
| Distribution | Distal > proximal; symmetric; feet before hands | Patchy; asymmetric; proximal involvement; face/trunk |
| Common causes | Diabetes; metabolic; toxic; idiopathic | Sjogren's; paraneoplastic; autoimmune; amyloidosis |
| Prognosis | Often slowly progressive | May be more aggressive; depends on etiology |
| Workup focus | Metabolic causes | Autoimmune and systemic causes |

---

## APPENDIX B: Skin Biopsy Interpretation

### Procedure
- **Sites:** Distal leg (10 cm above lateral malleolus) and proximal thigh (20 cm below iliac spine)
- **Technique:** 3mm punch biopsy; send to laboratory with PGP9.5 immunostaining capability
- **Processing:** Fix in PLP or Zamboni's fixative; immunostain for PGP9.5

### Interpretation

| Result | Interpretation |
|--------|----------------|
| IENFD below 5th percentile for age/sex/site | Diagnostic of SFN |
| IENFD at lower range of normal (5th-10th percentile) | Borderline; correlate clinically |
| Distal/proximal IENFD ratio >2:1 | Length-dependent pattern |
| Both sites equally reduced | Consider ganglionopathy or diffuse process |
| Sweat gland nerve fiber density reduced | Supports autonomic involvement |

### Normative Values (Approximate - Use Laboratory-Specific Norms)

| Site | Typical 5th Percentile Values |
|------|-------------------------------|
| Distal leg (age 20-40) | ~8-9 fibers/mm |
| Distal leg (age 60-80) | ~4-5 fibers/mm |
| Proximal thigh | Generally higher than distal leg |

---

## APPENDIX C: Autonomic Testing Interpretation

### QSART (Quantitative Sudomotor Axon Reflex Test)

| Pattern | Interpretation |
|---------|----------------|
| Reduced sweat volume at distal sites (foot) with normal proximal | Length-dependent autonomic SFN |
| Globally reduced sweat volumes | Diffuse autonomic involvement |
| Normal QSART | Does not exclude SFN (may have sensory-predominant) |

### Autonomic Reflex Screen Components

| Test | What It Measures | Abnormality in SFN |
|------|------------------|-------------------|
| QSART | Postganglionic sudomotor function | Reduced sweat volumes |
| Heart rate variability | Cardiovagal function | Reduced HRV to deep breathing |
| Valsalva maneuver | Cardiovagal and adrenergic function | Abnormal BP/HR response |
| Tilt table test | Adrenergic function; orthostatic tolerance | Orthostatic hypotension or POTS |

### POTS (Postural Orthostatic Tachycardia Syndrome) Criteria
- HR increase ≥30 bpm (or ≥40 bpm if age 12-19) within 10 minutes of standing
- Absence of orthostatic hypotension (SBP drop <20 mmHg)
- Symptoms of orthostatic intolerance
- Duration ≥6 months
